CA2092045A1 - Erythromycin derivatives, preparation and use thereof - Google Patents

Erythromycin derivatives, preparation and use thereof

Info

Publication number
CA2092045A1
CA2092045A1 CA002092045A CA2092045A CA2092045A1 CA 2092045 A1 CA2092045 A1 CA 2092045A1 CA 002092045 A CA002092045 A CA 002092045A CA 2092045 A CA2092045 A CA 2092045A CA 2092045 A1 CA2092045 A1 CA 2092045A1
Authority
CA
Canada
Prior art keywords
hemiacetal
salt
erythromycin derivative
positions
hydroxyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002092045A
Other languages
French (fr)
Other versions
CA2092045C (en
Inventor
Setsuo Harada
Yasunori Funabashi
Nobuhiro Inatomi
Shigeharu Tanayama
Seiichi Tanida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kitasato Institute
Takeda Pharmaceutical Co Ltd
Original Assignee
Kitasato Institute
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kitasato Institute, Takeda Chemical Industries Ltd filed Critical Kitasato Institute
Publication of CA2092045A1 publication Critical patent/CA2092045A1/en
Application granted granted Critical
Publication of CA2092045C publication Critical patent/CA2092045C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides
    • C12P19/60—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin
    • C12P19/62—Preparation of O-glycosides, e.g. glucosides having an oxygen of the saccharide radical directly bound to a non-saccharide heterocyclic ring or a condensed ring system containing a non-saccharide heterocyclic ring, e.g. coumermycin, novobiocin the hetero ring having eight or more ring members and only oxygen as ring hetero atoms, e.g. erythromycin, spiramycin, nystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins

Abstract

Disclosed are (1) a structurally novel 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which has an excellent gastrointestinal function promoting effect and is low in toxicity; (2) a process for preparing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof, which comprises reacting a 6,9-hemiacetal-erythromycin derivative or a salt thereof with an organism-derived oxidase; and (3) a gastrointestinal function promoting agent containing a 6,9-hemiacetal-erythromycin derivative having a hydroxyl group at at least one of the 14- and 15-positions or a salt thereof.
CA002092045A 1992-03-19 1993-03-19 Erythromycin derivatives, preparation and use thereof Expired - Fee Related CA2092045C (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP6424392 1992-03-19
JP64243/1992 1992-03-19
JP152467/1992 1992-06-11
JP15246792 1992-06-11

Publications (2)

Publication Number Publication Date
CA2092045A1 true CA2092045A1 (en) 1993-09-20
CA2092045C CA2092045C (en) 2004-08-10

Family

ID=26405362

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002092045A Expired - Fee Related CA2092045C (en) 1992-03-19 1993-03-19 Erythromycin derivatives, preparation and use thereof

Country Status (5)

Country Link
US (2) US5470961A (en)
EP (1) EP0561413B1 (en)
AT (1) ATE138925T1 (en)
CA (1) CA2092045C (en)
DE (1) DE69302938T2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE138925T1 (en) * 1992-03-19 1996-06-15 Takeda Chemical Industries Ltd ERYTHROMYCIN DERIVATIVES, PRODUCTION AND USE THEREOF
US6077943A (en) * 1996-03-01 2000-06-20 Takeda Chemical Industries, Ltd. Method of producing erythromycin derivative
CA2399198A1 (en) 2000-02-18 2001-08-23 Christopher Carreras Motilide compounds
CA2437576A1 (en) 2001-02-15 2002-08-22 Kosan Biosciences, Inc. Method for evaluating therapeutic efficacy
WO2004111077A1 (en) 2003-06-18 2004-12-23 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor
US20050113319A1 (en) * 2003-08-26 2005-05-26 Christopher Carreras 11-Deoxy-6,9-ether erythromycin compounds
US7407941B2 (en) * 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
US7211568B2 (en) * 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
US7582611B2 (en) 2005-05-24 2009-09-01 Pfizer Inc. Motilide compounds
EP1960414A4 (en) * 2005-12-08 2008-12-17 Pfizer Method for demethylating the 3'-dimethylamino group of erythromycin compounds
JP5684474B2 (en) 2006-09-11 2015-03-11 オセラ セラピューティクス， インコーポレイテッド Macrocyclic antagonist of motilin receptor for the treatment of gastrointestinal dysmotility disease
ES2401467T3 (en) 2006-12-05 2013-04-19 Bristol-Myers Squibb Company Motilide polymorphs
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2926959A1 (en) * 1979-07-04 1981-01-22 Hoechst Ag DEVICE FOR LIQUID-LIQUID EXTRACTION
US5008249A (en) * 1985-08-31 1991-04-16 Kitasato Kenkyusho Therapeutic method of stimulating digestive tract contractile motion in mammals
DE3689758T2 (en) * 1985-08-31 1994-08-18 Kitasato Inst Erythromycin derivative and process for its preparation.
US4672056A (en) * 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
JPH0633312B2 (en) * 1986-05-02 1994-05-02 大正製薬株式会社 14-Hydroxyerythromycin derivative and method for producing the same
US5106961A (en) * 1987-05-26 1992-04-21 Eli Lilly And Company Erythromycin ring-contracted derivatives
US4920102A (en) * 1988-04-18 1990-04-24 Eli Lilly And Company Method for treating gastrointestinal disorders
ATE138925T1 (en) * 1992-03-19 1996-06-15 Takeda Chemical Industries Ltd ERYTHROMYCIN DERIVATIVES, PRODUCTION AND USE THEREOF

Also Published As

Publication number Publication date
CA2092045C (en) 2004-08-10
DE69302938D1 (en) 1996-07-11
DE69302938T2 (en) 1996-10-17
EP0561413B1 (en) 1996-06-05
EP0561413A1 (en) 1993-09-22
US5470961A (en) 1995-11-28
US5854407A (en) 1998-12-29
ATE138925T1 (en) 1996-06-15

Similar Documents

Publication Publication Date Title
WO1991018866A3 (en) 1,4-diamino-2,3-dihydroxybutanes
AU8003287A (en) 8,9-dihydro-and/or 10,11-dihydro-avermectin derivatives
CA2212856A1 (en) Benzopyran-containing compounds and method for their use
EP0505572A4 (en) Iridoide derivative and its use as medicine
AU6020494A (en) Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
CA2092045A1 (en) Erythromycin derivatives, preparation and use thereof
CA2145826A1 (en) Lipopeptide derivatives, a process for their preparation and their use
CA2263563A1 (en) Cyclopentenones, process for preparing the same, and the use thereof
CA2015296A1 (en) Pyranyl cyanoguanidine derivatives
SE9003476L (en) NOVEL ISOINDOLE DERIVATIVES AND SALTS THEREOF, PROCESS FOR PRODUCING THE SAME AND ANTITUMOR AGENT COMPRISING THE SAME
CA2219656A1 (en) Antibacterial cephalosporins
AU7239794A (en) Process for preparing 5,8-dihydronaphthoquinone derivatives, novel 5,8-dihydronaphthoquinone derivatives and their use as anticancer agent
GR3015160T3 (en) Peroxyacid-clathrates, their preparation and their uses.
AU2597688A (en) 2,2-difluorocyclopropylethane derivatives, process for their preparation and their use as pesticides
CA2183050A1 (en) Sulfonyl- or sulfinylbenzoylguanidine derivatives
CA2170645A1 (en) Process for the preparation of n-methyl-3-(1-methyl-4-piperidinyl)-14-indole-5-ethanesulphonamide
AU4926190A (en) 2,3,23-trihydroxy-urs-12-ene and its derivatives, processes for their preparation and their use
AU2890289A (en) Disulphide derivatives as linking agent
CA2263846A1 (en) Novel pyranoside derivatives
CA2130618A1 (en) Stereoselective process for preparing .beta.-anomer enriched 2-deoxy-2,2-difluoro-d-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonate intermediates
AU632578B2 (en) Dibenzo (1,5) dioxocin-5-one derivatives, their use in medicaments and processes for their preparation
AU1254188A (en) Disaccharide derivatives
EP0297594A3 (en) Novel 3',4'-dinitrogen substituted epipodophyllotoxin glucoside derivatives
CA2168192A1 (en) 4-aminobenzoylguanidine derivatives
AU644474B2 (en) Heteroarylmethylbenzenes

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed